1. Introduction
===============

As an envelope glycoprotein, the spike protein of severe acute respiratory syndrome coronavirus (SARS-CoV) plays a key role in the viral entry and neutralization ([@bib2], [@bib7], [@bib36], [@bib51], [@bib55]). This structural protein consists of two functional regions: the outer globular S1 region responsible for the initial attachment to cellular receptor and the inner stalk S2 region contributing to the subsequent fusion between viral envelope and cellular membrane ([@bib3], [@bib24], [@bib41], [@bib50]). A membrane-associated zinc metallopeptidase, angiotensin-converting enzyme 2 (ACE2), has been identified as the functional receptor for SARS-CoV ([@bib37]). And a soluble form of ACE2 could block the association of S1 region with the permissive Vero E6 cells ([@bib37], [@bib42]). In addition, a 193-amino acid fragment (residues 318--510), located within the S1 region, was demonstrated as an independently folded receptor-binding domain (RBD) capable of attaching ACE2 more efficiently (IC~50~  \< 10 nM) compared with the full S1 region (IC~50~  ≈ 50 nM)([@bib49]). Besides, this RBD was able to elicit highly potent neutralizing antibodies in the immunized animals, which conferred those animals significant protection from the challenge of pathogenic SARS-CoV ([@bib8], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib53], [@bib54]). Moreover, a human monoclonal antibody 80R, isolated from a nonimmune human antibody library, was shown to potently neutralize SARS-CoV through targeting the RBD and blocking receptor recognition ([@bib45]). The epitope mapping illustrated a 180-amino acid conformationally sensitive fragment (residues 324--503) within the RBD was the neutralizing epitope of 80R ([@bib46]). Furthermore, another human monoclonal antibody m396 also exhibited potent neutralization of SARS-CoV by competition with ACE2 for binding to RBD ([@bib43]). Together those data suggest the receptor association process of SARS-CoV is an attractive opportunity for therapeutic intervention ([@bib6], [@bib15], [@bib24], [@bib28], [@bib35], [@bib52]). The peptide or peptidomimetic antagonist leads, including the SARS-CoV spike RBD, the soluble form of ACE2 and the neutralizing antibodies 80R plus m396, should be able to potently abolish viral attachment to host cells. In this study, we conducted structural bioinformatics analyses on the crystal structures of the SARS-CoV RBD complexed with functional receptor or neutralizing antibody ([@bib26], [@bib38], [@bib40], [@bib43]) to predict single substitutions on spike RBD, receptor or antibodies possibly causing remarkable elevation in the binding affinities of complexes for the design and development of anti-SARS agents.

2. Materials and methods
========================

Three coordinates files were retrieved from the Protein Data Bank (PDB) ([@bib4]). One file is the ACE2-bound RBD (PDB code: 2AJF) ([@bib38]), while the others are the RBD complexed with 80R (PDB code: 2GHW) ([@bib26]) or m396 (PDB code: 2DD8)([@bib43]). Both the first and second files harbor a pair of sister complexes. And in the third file, either the heavy chain or the light chain of m396 makes its own contacts with the RBD. Thus, a total of six complex structures (AE/BF for ACE2-RBD, AB/CD for 80R-RBD and HS/LS for m396-RBD) are subject to computational simulations, respectively. Firstly, the program FoldX ([@bib44]), based on an empirical effective energy function, was employed for calculation of the binding free energy values of wild type complexes. Then, a computational alanine scanning on the protein-protein interfaces was performed for evaluation of energetical contribution from single binding sites to the complex formation. Those positions yielding a calculated increase in association energy of more than 1 kcal/mol on alanine substitution were defined as energetic hot (important) spots according to previous criteria ([@bib10], [@bib9], [@bib30], [@bib31], [@bib32]). The next step was to redesign the interactions between RBD and its binding partners through the software DeepView ([@bib1], [@bib11]). Each of the binding sites on the RBD, receptor or antibody was saturated with virtual substitutions, i.e., replaced with all the 20 natural amino acid residues except the original one. Finally, the reconstructed models were feed to the program FoldX to compute their binding energies. Here, only the variants rewarded a value of at least 1 kcal/mol lower than that of the wild type were taken into consideration.

3. Results and discussion
=========================

The calculated binding energy values and hot spots of the wild type complexes are shown in [Table 1](#tbl1){ref-type="table"} . The complexes ACE2-RBD (AE/BF) and 80R-RBD (AB/CD) show a close correlation between their interaction energies (−15.78/−14.82 kcal/mol versus −18.36/−16.53 kcal/mol) and buried surface area (1700 Å^2^ versus 2200 Å^2^), gap volume (7000 Å^3^ versus 4000 Å^3^), or binding affinity (1.70 nM versus 1.59 nM)([@bib26]). Those obvious associations indicate that the higher geometric complementarity, corresponding to the larger buried surface area and the smaller gap volume, offers the complex 80R-RBD rather than the complex ACE2-RBD the lower interaction energy and consequently the stronger binding affinity. Similarly, the correlation of binding energy with buried surface area is also found for the complex m396-RBD in which the heavy chain and the light chain contribute 66% and 34% to the total buried surface ([@bib43]). And the RBD association energy of the former chain (−8.64 kcal/mol) is remarkably lower than that of the latter (−5.42 kcal/mol). The perfect agreements of computational predictions with structural observations or biochemical evidences strongly suggest the reliability of our protocols.Table 1Calculated binding free energies and hot spots of wild type complexesComplexBinding free energy (kcal/mol)Hot spotsAE−15.78Chain A: GLU37, ASP38, TYR41; chain E: ARG426, TYR436, TYR475, TYR484, TYR491BF−14.82Chain B: GLU37, TYR41, LYS353; chain F: ARG426, TYR436, ASN473, TYR475, TYR484, TYR491AB−18.36Chain A: TYR436, PRO470, LEU472, ASP480, TYR484, TYR491; chain B: TYR102, ASN164, ARG223, TRP226CD−16.53Chain C: TYR436, PRO470, ASP480, TYR484; chain D: TYR102, ASN164, ARG223, TRP226HS−8.64Chain H: none; chain S: TYR491, GLN492LS−5.42Chain L: TRP91, ASP92; chain S: ILE489[^1]

As to the hot spots of complexes, the consistency between computational predictions and experimental evidences is clearly detected for RBD and receptor. In ACE2-RBD complexes, three receptor residues (GLU37, ASP38 and TYR41 on the chain A of complex AE or GLU37, TYR41 and LYS353 on the chain B of complex BF) form one hot spot cluster interacting with another hot cluster formed by five or six RBD residues (ARG426, TYR436, TYR475, TYR484 and TYR491 on the chain E of complex AE and the chain F of complex BF, whereas ASN473 only on the chain F). The interactions between the two hot clusters make the major contribution to the binding free energy of ACE2-RBD complexes. Notably, our predictions are in agreement with previous experimental alanine mutagenesis, which identified two hot spots on RBD (ARG426 and ASN473) ([@bib5]) and another two on receptor (TYR41 and LYS353) ([@bib39]). In addition, computational alanine scanning on the sister complexes AB and CD successfully identify a RBD hot spot (ASP480) revealed in mutational binding analyses ([@bib46]). In sharp contrast to ACE2, the antibody 80R possesses four hot residues (TYR102, ASN164, ARG223 and TRP226) being scattered on the binding surface rather than centralized into a cluster. The difference in the number and distribution of hot spots might account for the large gap between the interaction energies of 80R-RBD (−18.3627 and −16.5309 kcal/mol) and those of ACE2-RBD (−15.7765 and −14.8160 kcal/mol), the stronger competence of 80R with soluble ACE2 for association with RBD, or the higher spike-binding affinity of 80R compared to that of receptor. Finally, only two neighboring hot spots (TRP91 and ASP92) are found on the light chain of m396 while none on the heavy chain. Thus, an interesting discovery is the fact that among the five or six ACE2-binding hot spots of RBD, three (TYR436, TYR484 and TYR491) are simultaneously 80R-neutralizing hot spots whereas only one (TYR491) is important for m396 neutralization. This finding indicates that 80R might have the greater potential than m396 for inhibition of spike-mediated infection. In summary, the consistency of calculations with experiments mentioned above further validates our approaches to characterize protein--protein interactions.

The predicted replacements on spike RBD, cellular receptor or neutralizing antibody with significant increase in binding affinity are listed in [Table 2](#tbl2){ref-type="table"} . The comparisons between virtual mutants derived from sister complexes of ACE2-RBD or 80R-RBD consistently identify a number of substitutions worth of biochemical and immunological experimental tests. For instance, recent experimental evidences revealed the great potential of ACE2 in the protection of several animal models from SARS-CoV-induced lung injury or severe acute lung failure ([@bib27], [@bib33], [@bib34]). Simultaneously, the crystal structures of the native and inhibitor-bound forms of ACE2 ([@bib35], [@bib47], [@bib48]) successfully laid a solid foundation for the discovery of novel small-molecule inhibitors of its enzymatic activity or spike-mediated virus entry by chemical genetics ([@bib25], [@bib29]) and the identification of its crucial active-site residues by site-directed mutagenesis ([@bib12], [@bib13]). Very recently, a modest anti-SARS activity (IC~50~  ≈ 0.1 mM) was observed for an ACE2-derived peptide containing two segments of receptor (residues 22--44 and 351--357) linked by glycine ([@bib14]). It should be pointed out that both the experimentally confirmed hot spots (TYR41 and LYS353) and the predicted sites for replacements (THR27, LYS31 and HIS34) are nested in those two segments. Similarly, a small peptide derived from spike protein (residues 483--493) also block viral receptor recognition with IC~50~ of 6.99 nM ([@bib23]). And our calculated two hot spots (TYR484 and TYR491) in combination with two target positions (TYR484 and GLN492) are located in this short fragment, too. Consequently, it is reasonable to anticipate that our blueprint could effectively increase the binding affinity of the two novel peptides to disrupt SARS-CoV infection.Table 2Predicted replacements with significant increase in binding affinityProteinResidueReplacementRBDLEU443ARG/TRPLEU472PHEASN479PHE/TRP/TYRTYR484TRPGLN492ARG  ACE2THR27ILE/METLYS31ILEHIS34PHE/TRP  80RSER101ILE/MET/VALARG162ASN/HISSER163HIS/PHE/THR/VALASP182CYS/GLU/TRPSER184VALTHR185ARG/ASN/LEU/METSER195CYS/ILE/TRP/VALSER199MET/TYRTHR206PHE/TRP  m396 (H chain)SER31GLU/ILE/LEU/MET/PHE/VALTYR32HIS/PHETHR52CYSASN58ARG/CYS/HIS/ILE/LEU/MET/SER/THR/TRP/TYR/VALTHR96GLUVAL97ASP  m396 (L chain)SER30HIS/ILE/MET/TYRSER93HIS/ILE/LEU/TYR/VAL

[^1]: The complexes AE and BF with the chains A, B for ACE2 and the chains E, F for RBD; the complexes AB and CD with the chains A, C for RBD and the chains B, D for 80R; the complexes HS and LS with the chains H, L and S for heavy and light chains of m396 plus RBD.
